2016
DOI: 10.1093/annonc/mdw337.59
|View full text |Cite
|
Sign up to set email alerts
|

Docetaxel and stealth liposomal doxorubicin in relapsed breast cancer as salvage treatment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2019
2019

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…1 For oncological patients with metastasis is the most used chemotherapeutic doxorubicin (DOX). 2 Treatment response is in the range of 25% and 33%, with a median progression of 3.6 months and a median survival of 8.9 months. Despite DOX therapeutic efficacy it exhibits high cardiotoxicity.…”
Section: Introductionmentioning
confidence: 99%
“…1 For oncological patients with metastasis is the most used chemotherapeutic doxorubicin (DOX). 2 Treatment response is in the range of 25% and 33%, with a median progression of 3.6 months and a median survival of 8.9 months. Despite DOX therapeutic efficacy it exhibits high cardiotoxicity.…”
Section: Introductionmentioning
confidence: 99%